Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog IGF-1 LR3 | Synthetic analog Hexarelin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 411 | 1,112 | |
| Evidence level | Results from animal studies only | Has results from studies in people | |
| Safety | |||
| Safety results | 7 (0 in people) | 21 (13 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | None registered | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | IGF-1 LR3 | Hexarelin |
|---|---|---|
| Growth hormone and IGF-1Reproductive and sexual health | 27252 | 36927089 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026).
| Stress hormonesEndocrine and hormones | 11 | 87843 |
|---|
| Heart functionCardiovascular | 963 | 151199141 |
|---|
| Receptor activity and mechanismSkin and wound | 40634 | 105123801 |
|---|
| PharmacokineticsPharmacology | 32311 | 5052916 |
|---|
| Sex hormones and fertilityReproductive and sexual health | 531340 | 615 |
|---|
| Glycemic controlMetabolic and weight | 29272 | 153111 |
|---|
| Body weightWhole body | 3333 | 1129 |
|---|
| Bone and jointMusculoskeletal | 44 | 286193 |
|---|
| NeuroprotectionNervous system and cognition | 44 | 301812 |
|---|
| Blood pressureCardiovascular | 422 | 761 |
|---|
| Inflammation markersImmune and inflammation | 11 | 222173 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
IGF-1 LR3 differs from Insulin-like growth factor I (IGF-I, somatomedin C; native form = mecasermin) at 14 positions and carries 3 added groups.
What is different
Hexarelin differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | IGF-1 LR3 | Hexarelin |
|---|---|---|
| Stress hormonesEndocrine and hormonesCompared as: value in the arm that got the peptide, in ng/l x 125 min | No randomized trial result 1 result from other study designs. | 3444 ng/L x 125 min ACTH AUC n = 151999 |
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in mu/l | No randomized trial result 27 results from other study designs. | 6.8 mU/l Peak GH · hexarelin 0.5 microgram/kg during SS50 Dose studied: 0.5 microgram/kgn = 121997 |
| Blood pressureCardiovascularCompared as: value in the arm that got the peptide, in mm hg | No randomized trial result 4 results from other study designs. | 92.8 mm Hg MBP n = 71999 |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in % | No randomized trial result 9 results from other study designs. | 70.7% LVEF n = 71999 |
No randomized trial result
27 results from other study designs.
6.8 mU/l
Peak GH · hexarelin 0.5 microgram/kg during SS50
Dose studied: 0.5 microgram/kgn = 121997
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.